Mariner
ACRS icon

Mariner’s Aclaris Therapeutics ACRS Stock Holding History

Mariner’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,670
Closed -$50.2K – 3549
2025
Q4 		$50.2K Buy
16,670
+558
+3% +$1.41K ﹤0.01% 3414
2025
Q3 		$30.6K Sell
16,112
-4,898
-23% -$8.54K ﹤0.01% 3485
2025
Q2 		$29.8K Sell
21,010
-16,959
-45% -$22.9K ﹤0.01% 3387
2025
Q1 		$58.1K Buy
37,969
+195
+0.5% +$416 ﹤0.01% 3291
2024
Q4 		$93.7K Sell
37,774
-10,327
-21% -$25.7K ﹤0.01% 3199
2024
Q3 		$55.3K Buy
48,101
+5,905
+14% +$7.24K ﹤0.01% 3180
2024
Q2 		$46.4K Buy
42,196
+2,396
+6% +$2.82K ﹤0.01% 3069
2024
Q1 		$49.4K Buy
39,800
+3,143
+9% +$3.75K ﹤0.01% 3031
2023
Q4 		$38.5K Buy
+36,657
New +$112K ﹤0.01% 2960

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Mariner's ACRS Position: Q1 2026 in Review

Mariner sold out of Aclaris Therapeutics (ACRS) in Q1 2026, closing a stake of 16,670 shares — an estimated $50.2K sold.

Mariner first reported a position in ACRS in Q4 2023 and held it in 9 quarters. The position peaked at $93.7K in Q4 2024. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Mariner reported no remaining Aclaris Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Mariner sold 16,670 Aclaris Therapeutics shares in Q1 2026, an estimated $50.2K.
  • Mariner first reported a position in Aclaris Therapeutics in Q4 2023 and held it in 9 quarters.
  • Mariner's Aclaris Therapeutics position peaked at $93.7K in Q4 2024.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.